They discovered that TP53 mutations were observed mainly in patients with intermediate-2 or high-risk disease according to the International Prognostic Scoring System (IPSS) and described a correlation with thrombocytopenia, an increased number of blasts and CK. Here, TP53 is linked to Thrombocytopenia.